Stockscreener 앱 받기
2.90
0.35%
0.010
전일 마감가:
$2.89
열려 있는:
$2.88
하루 거래량:
133.14K
Relative Volume:
0.39
시가총액:
$111.10M
수익:
$2.76M
순이익/손실:
$-49.12M
주가수익비율:
-1.9333
EPS:
-1.5
순현금흐름:
$-46.21M
1주 성능:
+9.43%
1개월 성능:
+1.40%
6개월 성능:
-50.34%
1년 성능:
-37.23%
1일 변동 폭
$2.79
$2.94
1주일 범위
$2.5956
$3.01
52주 변동 폭
$2.37
$8.8699
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
명칭
Orchestra Biomed Holdings Inc
전화
646-343-9298
주소
150 UNION SQUARE DRIVE, NEW HOPE
OBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
2.90 | 101.53M | 2.76M | -49.12M | -46.21M | -1.50 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-20 | 개시 | BTIG Research | Buy |
| 2025-01-02 | 개시 | Barclays | Overweight |
| 2024-08-22 | 개시 | H.C. Wainwright | Buy |
| 2024-07-25 | 개시 | B. Riley Securities | Buy |
| 2024-01-19 | 개시 | Jefferies | Buy |
| 2023-02-24 | 개시 | Piper Sandler | Overweight |
| 2023-02-07 | 개시 | Chardan Capital Markets | Buy |
모두보기
Orchestra Biomed Holdings Inc 주식(OBIO)의 최신 뉴스
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs - MyChesCo
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation - MSN
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Chardan Capital Maintains Buy Rating on OBIO with $20 Price Targ - GuruFocus
Barclays PLC Boosts Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Wells Fargo & Company MN Buys 3,992 Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
Orchestra BioMed HoldingsBreakthrough Device Designation Gives Speculative Optimism - Seeking Alpha
Orchestra BioMed (OBIO) Surpasses Revenue Estimates with Strong Q1 Growth | OBIO Stock News - GuruFocus
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy and IDE Approval for Virtue SAB Trial - Nasdaq
Orchestra BioMed Reports First Quarter 2025 Financial - GlobeNewswire
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones - Stock Titan
4 No-Brainer Stocks to Buy Right Now - The Globe and Mail
(OBIO) On The My Stocks Page - news.stocktradersdaily.com
Orchestra BioMed receives FDA approval to initiate Virtue Trial - Med-Tech Insights
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Sold by Price T Rowe Associates Inc. MD - The AM Reporter
RTW INVESTMENTS, LP Increases Stake in Orchestra BioMed Holdings Inc - GuruFocus
ORCHESTRA BIOMED Earnings Preview: Recent $OBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual - GlobeNewswire
Orchestra BioMed (OBIO) Expands Patent Portfolio for AVIM Therap - GuruFocus
Orchestra BioMed Expands Patent Portfolio with 10 New Patents for Hypertension Treatment, Totaling 120 Global Patents - Nasdaq
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure - GlobeNewswire
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
BlackRock, Inc. Reduces Stake in Orchestra BioMed Holdings Inc. - GuruFocus
Orchestra BioMed (NASDAQ:OBIO) Price Target Lowered to $12.00 at Barclays - Defense World
Orchestra BioMed Holdings (OBIO) Target Price Adjustment by Barc - GuruFocus
Barclays Adjusts Price Target for Orchestra BioMed (OBIO) | OBIO Stock News - GuruFocus
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Shares Bought by JPMorgan Chase & Co. - Defense World
OBIO: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
How did Orchestra BioMed Holdings Inc (OBIO) fare last session? - uspostnews.com
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment - MyChesCo
Orchestra Biomed sees $149,201 stock purchase by RTW Investments By Investing.com - Investing.com Australia
Orchestra BioMed Holdings Inc [OBIO] Records 200-Day SMA of $5.25 - knoxdaily.com
Orchestra BioMed to Present at Jefferies Global Healthcare Conference - MyChesCo
Geode Capital Management LLC Boosts Stock Holdings in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) - Defense World
FDA approves head-to-head trial of Orchestra BioMed’s balloon - Investing.com
Orchestra BioMed (OBIO) Gains FDA Nod for Updated Coronary ISR T - GuruFocus
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy - Diagnostic and Interventional Cardiology
FDA Clears Orchestra BioMed's Virtue SAB Trial To Treat Coronary ISR - Nasdaq
Orchestra BioMed Receives FDA Approval for IDE Amendment - TipRanks
Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon - marketscreener.com
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon - The Manila Times
Orchestra BioMed's Revolutionary Sirolimus Balloon Gets FDA Green Light for Head-to-Head Trial - Stock Titan
FDA approves head-to-head trial of Orchestra BioMed’s balloon By Investing.com - Investing.com Canada
Orchestra BioMed (NASDAQ:OBIO) Shares Down 6.1% – Time to Sell? - Defense World
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - GlobeNewswire
Orchestra BioMed Secures Triple Conference Lineup: CEO Sets Major Investor Presentations - Stock Titan
Analyzing PetVivo (NASDAQ:PETV) & Orchestra BioMed (NASDAQ:OBIO) - Defense World
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 - MSN
Orchestra Biomed Holdings Inc (OBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Orchestra Biomed Holdings Inc 주식 (OBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10% Owner |
Apr 29 '25 |
Buy |
2.53 |
50,000 |
126,500 |
8,256,163 |
| Aryeh Jason | Director |
Dec 27 '24 |
Option Exercise |
4.30 |
11,700 |
50,310 |
80,060 |
| Hochman David P | See Remarks |
Dec 23 '24 |
Buy |
4.66 |
4,000 |
18,640 |
579,498 |
| Taylor Andrew Lawrence | Chief Financial Officer |
Dec 19 '24 |
Buy |
4.83 |
1,000 |
4,830 |
344,960 |
| Hochman David P | See Remarks |
Dec 18 '24 |
Buy |
4.91 |
5,000 |
24,550 |
575,498 |
| Hochman David P | See Remarks |
Sep 25 '24 |
Buy |
4.75 |
7,500 |
35,630 |
335,002 |
| Hochman David P | See Remarks |
Sep 24 '24 |
Buy |
4.91 |
2,500 |
12,275 |
570,498 |
| Sherman Darren | See Remarks |
Sep 09 '24 |
Sale |
5.48 |
6,804 |
37,286 |
772,691 |
| Sherman Darren | See Remarks |
Sep 10 '24 |
Sale |
5.31 |
6,904 |
36,660 |
765,787 |
| Fain Eric S | Director |
Sep 06 '24 |
Sale |
5.64 |
2,000 |
11,280 |
44,810 |
1.54%
7.58%
자본화:
|
볼륨(24시간):